Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Sales (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Return on Sales for 7 consecutive years, with 16.89% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 4864.0% year-over-year to 16.89%, compared with a TTM value of 2.79% through Sep 2025, up 1213.0%, and an annual FY2024 reading of 14.4%, changed N/A over the prior year.
  • Return on Sales was 16.89% for Q3 2025 at X4 Pharmaceuticals, down from 13.05% in the prior quarter.
  • Across five years, Return on Sales topped out at 161.34% in Q2 2024 and bottomed at 65.53% in Q3 2024.
  • Average Return on Sales over 4 years is 26.21%, with a median of 23.11% recorded in 2022.
  • The sharpest move saw Return on Sales soared 11281bps in 2024, then plummeted -17438bps in 2025.
  • Year by year, Return on Sales stood at 25.44% in 2022, then surged by 76bps to 44.82% in 2023, then plummeted by -159bps to 26.55% in 2024, then skyrocketed by 36bps to 16.89% in 2025.
  • Business Quant data shows Return on Sales for XFOR at 16.89% in Q3 2025, 13.05% in Q2 2025, and 0.01% in Q1 2025.